MétaCan
Menu
Back to cohort
Record W2946105917 · doi:10.1093/eurheartj/ehz299

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

2019· article· en· W2946105917 on OpenAlexaff
Harvey D. White, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Jay M. Edelberg, Andrejs Ērglis, Shaun G. Goodman, Corinne Hanotin, Robert A. Harrington, J. Wouter Jukema, Renato D. Lópes, Kenneth W. Mahaffey, Angèle Moryusef, Robert Pordy, Matthew T. Roe, Piyamitr Sritara, Pierluigi Tricoci, Andreas M. Zeiher, Gregory G. Schwartz

Bibliographic record

VenueEuropean Heart Journal · 2019
Typearticle
Languageen
FieldMedicine
TopicLipoproteins and Cardiovascular Health
Canadian institutionsCanadian VIGOUR CentreUniversity of TorontoUniversity of AlbertaSt. Michael's Hospital
FundersAmerican RegentGenentechEsperion TherapeuticsIdorsia PharmaceuticalsDuke Clinical Research InstituteAstellas PharmaEisaiBayer HealthCareMedicines CompanyRegado BiosciencesVerily Life SciencesAstraZenecaAmarin CorporationIronwood Pharmaceuticals, IncorporatedSt. Jude MedicalFlatiron HealthGreen Lane Research and Educational FundRegeneron PharmaceuticalsAbbott VascularBoston VA Research InstituteBoston Scientific CorporationEli Lilly and CompanyCleveland ClinicBristol-Myers SquibbCSL BehringBelvoir Media GroupNovo NordiskMyoKardiaJanssen PharmaceuticalsAblynxDaiichi Sankyo EuropeServierGilead SciencesGlaxoSmithKlineAmgenPfizerSanofiAmerican Heart Association
KeywordsMedicineAlirocumabMyocardial infarctionCardiologyInternal medicinePCSK9Intensive care medicineCholesterolLipoproteinLDL receptor

Abstract

fetched live from OpenAlex

AIMS: The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin-kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. METHODS AND RESULTS: Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77-0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77-0.99; P = 0.032) and Type 2 (0.77, 0.61-0.97; P = 0.025), but not Type 4 MI. CONCLUSION: After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.391
Threshold uncertainty score0.266

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.268
Teacher spread0.251 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations69
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart JournalSame topicLipoproteins and Cardiovascular HealthFrench-language works237,207